OCULAR THERAPEUTIX, INC Deferred Revenue
OCULAR THERAPEUTIX, INC (OCUL) had Deferred Revenue of $42.00 thousand as of 2015-12-31, per its 10-K filed 2017-03-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2017-03-10
- 2015-12-31: Deferred Revenue, Current $42.00K.
- 2015-09-30: Deferred Revenue, Current $83.00K.
- 2015-06-30: Deferred Revenue, Current $125.00K.
- 2015-03-31: Deferred Revenue, Current $250.00K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2015-12-31 | $42.00K 10-K · filed 2017-03-10 |
| 2015-09-30 | $83.00K 10-Q · filed 2015-11-10 |
| 2015-06-30 | $125.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $250.00K 10-Q · filed 2015-05-15 |
| 2014-12-31 | $188.00K 10-K · filed 2016-03-10 |
| 2014-09-30 | $250.00K 10-Q · filed 2014-11-12 |
| 2014-06-30 | $250.00K 10-Q · filed 2014-08-29 |
| 2013-12-31 | $250.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |